Compare Enveric Biosciences Inc (ENVB) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Icl Group Ltd — how do they compare? Enveric Biosciences Inc trades at $1.43 (market cap $5.32M), while Icl Group Ltd trades at $5.05 (market cap $6.57B). The key difference: Icl Group Ltd is far larger — about 1235× Enveric Biosciences Inc's market cap, and Icl Group Ltd pays a 3.74% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | ICL | |
|---|---|---|
Market Cap | $5.32M | $6.57B |
Sector | Health | Basic Materials |
52-Week High | $17.40 | $7.03 |
52-Week Low | $1.28 | $4.80 |
Enterprise Value | $408.82K | $9.14B |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
ICL trades at $5.045, up 0.7% with bearish technical signals despite recent earnings beats. The company maintains stable cash flow with $1.06B from operations in 2025, though revenue has declined from $10B in 2022 to $7.15B in 2025. Recent $800M senior notes offering strengthens liquidity while analyst consensus remains entirely neutral with 4 hold ratings.
ICL faces margin compression with net income margin falling to 3.52% amid competitive pressures. The stock's 24.29 P/E suggests full valuation relative to earnings growth. Key risks include raw material cost inflation and foreign exchange volatility, though improved 2026 guidance provides modest upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
